# Ligandrol (LGD-4033)

*Also known as: LGD-4033, LGD, Anabolicum*

Potent SARM for lean mass; suppression evident at higher doses.

## Overview

Ligandrol (LGD-4033) is a non-steroidal selective androgen receptor modulator developed for conditions like muscle wasting and frailty. It binds the androgen receptor with high affinity, producing anabolic effects in skeletal muscle while attempting to spare prostate androgenic action. The compound shows a roughly 30-hour half-life, peak concentration around 3 hours, and roughly 60% bioavailability in available human data, supporting once-daily oral dosing. Phase I trials at 0.1-1 mg produced dose-dependent lean mass gains, and suppression of endogenous testosterone becomes evident at higher doses, often accompanied by mild lipid changes and liver enzyme shifts. As an investigational, unapproved SARM that is WADA-prohibited and frequently sold mislabeled or contaminated, harm reduction focuses on third-party verification, pre-and-on-cycle bloodwork (LH, FSH, total T, HDL/LDL, ALT/AST), and a planned PCT given the documented suppression.

## Pharmacokinetics

- **Model tier:** advanced
- **Half-life:** 1.3 days (30 hours)
- **Cmax:** 498 ng/mL
- **Tmax:** 0.1 days
- **Bioavailability:** 60%

## Dosing

- **Default dose:** 5 mg
- **Typical range:** 2–10 mg
- **Units:** ng/mL

## Harm reduction

- **Aromatizes:** No
- **Hepatotoxicity:** mild
- **Injection frequency:** Oral, daily

## Detection time (anti-doping)

- **Window:** 14–21 days post-last-dose
- **Target metabolite:** Dihydroxylated long-term metabolites (M5a, M2d)
- **Assay:** LC-HRMS/MS
- **Notes:** Long-term dihydroxylated metabolites extend detection to ~21 days.

## Source

- **Label:** PMC LGD-4033 PK
- **URL:** https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4111291/
- **Notes:** Tmax/Cmax estimated from 1 mg graph.

---

**Canonical URL:** https://anabolicdex.com/compounds/ligandrol
**Plot:** https://anabolicdex.com/plot?compound=ligandrol